Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens

Lan Zhao; Wanyi Fu; Biyuan Gao; Yi Liu; Shandong Wu; Zhi Chen; Xianqi Zhang; Huiying Wang; Yan Feng; Xueyan Wang; Hongtian Wang; Tianfei Lan; Meiling Liu; Xuefeng Wang; Yuemei Sun; Fangmei Luo; Gabriele Gadermaier; Fatima Ferreira; Serge A Versteeg; Jaap H Akkerdaas; Deyun Wang; Rudolf Valenta; Susanne Vrtala; Zhongshan Gao; Ronald van Ree

doi:10.1186/s13601-020-00354-7

Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens

Lan Zhao, Wanyi Fu, Biyuan Gao, Yi Liu, Shandong Wu, Zhi Chen, Xianqi Zhang, Huiying Wang, Yan Feng, Xueyan Wang, Hongtian Wang, Tianfei Lan, Meiling Liu, Xuefeng Wang, Yuemei Sun, Fangmei Luo, Gabriele Gadermaier, Fatima Ferreira, Serge A Versteeg, Jaap H AkkerdaasDeyun Wang, Rudolf Valenta, Susanne Vrtala, Zhongshan Gao, Ronald van Ree

Scientific Working Group Allergology and Immunology

Research output: Journal article (peer-reviewed) › Journal article

6 Citations (Scopus)

Abstract

BACKGROUND: Artemisia weed pollen allergy is important in the northern hemisphere. While over 350 species of this genus have been recorded, there has been no full investigation into whether different species may affect the allergen diagnosis and treatment. This study aimed to evaluate the variations in amino acid sequences and the content of major allergens, and how these affect specific IgE binding capacity in representative Artemisia species.

METHODS: Six representative Artemisia species from China and Artemisia vulgaris from Europe were used to determine allergen amino acid sequences by transcriptome, gene sequencing and mass spectrometry of the purified allergen component proteins. Sandwich ELISAs were developed and applied for Art v 1, Art v 2 and Art v 3 allergen quantification in different species. Aqueous pollen extracts and purified allergen components were used to assess IgE binding by ELISA and ImmunoCAP with mugwort allergic patient serum pools and individual sera from five areas in China.

RESULTS: The Art v 1 and Art v 2 homologous allergen sequences in the seven Artemisia species were highly conserved. Art v 3 type allergens in A. annua and A. sieversiana were more divergent compared to A. argyi and A. vulgaris. The allergen content of Art v 1 group in the seven extracts ranged from 3.4% to 7.1%, that of Art v 2 from 1.0% to 3.6%, and Art v 3 from 0.3% to 10.5%. The highest IgE binding potency for most Chinese Artemisia allergy patients was with A. annua pollen extract, followed by A. vulgaris and A. argyi, with A. sieversiana significantly lower. Natural Art v 1-3 isoallergens from different species have almost equivalent IgE binding capacity in Artemisia allergic patients from China.

CONCLUSION AND CLINICAL RELEVANCE: There was high sequence similarity but different content of the three group allergens from different Artemisia species. Choice of Artemisia annua and A. argyi pollen source for diagnosis and immunotherapy is recommended in China.

Original language	English
Article number	50
Pages (from-to)	50
Journal	Clinical and Translational Allergy
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s13601-020-00354-7
Publication status	Published - Dec 2020

Access to Document

10.1186/s13601-020-00354-7

Cite this

Zhao, L., Fu, W., Gao, B., Liu, Y., Wu, S., Chen, Z., Zhang, X., Wang, H., Feng, Y., Wang, X., Wang, H., Lan, T., Liu, M., Wang, X., Sun, Y., Luo, F., Gadermaier, G., Ferreira, F., Versteeg, S. A., ... van Ree, R. (2020). Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens. Clinical and Translational Allergy, 10(1), 50. [50]. https://doi.org/10.1186/s13601-020-00354-7

@article{1708e4dadb794a178ecb19e436b2f894,

title = "Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens",

abstract = "BACKGROUND: Artemisia weed pollen allergy is important in the northern hemisphere. While over 350 species of this genus have been recorded, there has been no full investigation into whether different species may affect the allergen diagnosis and treatment. This study aimed to evaluate the variations in amino acid sequences and the content of major allergens, and how these affect specific IgE binding capacity in representative Artemisia species.METHODS: Six representative Artemisia species from China and Artemisia vulgaris from Europe were used to determine allergen amino acid sequences by transcriptome, gene sequencing and mass spectrometry of the purified allergen component proteins. Sandwich ELISAs were developed and applied for Art v 1, Art v 2 and Art v 3 allergen quantification in different species. Aqueous pollen extracts and purified allergen components were used to assess IgE binding by ELISA and ImmunoCAP with mugwort allergic patient serum pools and individual sera from five areas in China.RESULTS: The Art v 1 and Art v 2 homologous allergen sequences in the seven Artemisia species were highly conserved. Art v 3 type allergens in A. annua and A. sieversiana were more divergent compared to A. argyi and A. vulgaris. The allergen content of Art v 1 group in the seven extracts ranged from 3.4% to 7.1%, that of Art v 2 from 1.0% to 3.6%, and Art v 3 from 0.3% to 10.5%. The highest IgE binding potency for most Chinese Artemisia allergy patients was with A. annua pollen extract, followed by A. vulgaris and A. argyi, with A. sieversiana significantly lower. Natural Art v 1-3 isoallergens from different species have almost equivalent IgE binding capacity in Artemisia allergic patients from China.CONCLUSION AND CLINICAL RELEVANCE: There was high sequence similarity but different content of the three group allergens from different Artemisia species. Choice of Artemisia annua and A. argyi pollen source for diagnosis and immunotherapy is recommended in China.",

author = "Lan Zhao and Wanyi Fu and Biyuan Gao and Yi Liu and Shandong Wu and Zhi Chen and Xianqi Zhang and Huiying Wang and Yan Feng and Xueyan Wang and Hongtian Wang and Tianfei Lan and Meiling Liu and Xuefeng Wang and Yuemei Sun and Fangmei Luo and Gabriele Gadermaier and Fatima Ferreira and Versteeg, {Serge A} and Akkerdaas, {Jaap H} and Deyun Wang and Rudolf Valenta and Susanne Vrtala and Zhongshan Gao and {van Ree}, Ronald",

note = "Funding Information: This study was carried out with financial support from Hangzhou Aileji Biotech Company, Hangzhou, China (Contract 2016R1), China-Austria Scientific Cooperation project (2019YFE0106600 and CN 14/2020), the National Natural Science Foundation of China (31772271) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201826). Funding Information: Gao ZS received a grant from Hangzhou Aileji Biotech Company, Hangzhou, China (Contract 2016R1). Gao ZS, Liu Y and Feng Y received funds from The Ministry of Science and Technology China (2019YFE0106600). Wang XY received a grant from Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201826). Rudolf Valenta has received research grants from Viravaxx, Vienna, Austria and HVD Life Sciences, Vienna, Austria and serves as a consultant for Viravaxx. Susanne Vrtala received funds from the Austrian government (CN 14/2020). A patent for Artemisia pollen allergen nsLTP quantification by ELISA has been applied in China (202011210352.1, pending) by ZS Gao, L Zhao, BY Gao and WY Fu. All other authors declare no conflict of interest. Funding Information: We thank professor Richard E. Goodman, Chairman of the Executive Committee of WHO/IUIS Allergen Nomenclature Sub-committee for evaluating and including new allergens reported in this paper. Dr. Ma Yintao participated in the sequencing of putative allergen genes with genomic DNAs. The authors thank Lingying Wu, Yifei Wang and Xiaojing Du for their assistance in sample collection and testing. Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

doi = "10.1186/s13601-020-00354-7",

language = "English",

volume = "10",

pages = "50",

journal = "Clinical and Translational Allergy",

issn = "2045-7022",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

Zhao, L, Fu, W, Gao, B, Liu, Y, Wu, S, Chen, Z, Zhang, X, Wang, H, Feng, Y, Wang, X, Wang, H, Lan, T, Liu, M, Wang, X, Sun, Y, Luo, F, Gadermaier, G, Ferreira, F, Versteeg, SA, Akkerdaas, JH, Wang, D, Valenta, R, Vrtala, S, Gao, Z & van Ree, R 2020, 'Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens', Clinical and Translational Allergy, vol. 10, no. 1, 50, pp. 50. https://doi.org/10.1186/s13601-020-00354-7

TY - JOUR

T1 - Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens

AU - Zhao, Lan

AU - Fu, Wanyi

AU - Gao, Biyuan

AU - Liu, Yi

AU - Wu, Shandong

AU - Chen, Zhi

AU - Zhang, Xianqi

AU - Wang, Huiying

AU - Feng, Yan

AU - Wang, Xueyan

AU - Wang, Hongtian

AU - Lan, Tianfei

AU - Liu, Meiling

AU - Wang, Xuefeng

AU - Sun, Yuemei

AU - Luo, Fangmei

AU - Gadermaier, Gabriele

AU - Ferreira, Fatima

AU - Versteeg, Serge A

AU - Akkerdaas, Jaap H

AU - Wang, Deyun

AU - Valenta, Rudolf

AU - Vrtala, Susanne

AU - Gao, Zhongshan

AU - van Ree, Ronald

N1 - Funding Information: This study was carried out with financial support from Hangzhou Aileji Biotech Company, Hangzhou, China (Contract 2016R1), China-Austria Scientific Cooperation project (2019YFE0106600 and CN 14/2020), the National Natural Science Foundation of China (31772271) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201826). Funding Information: Gao ZS received a grant from Hangzhou Aileji Biotech Company, Hangzhou, China (Contract 2016R1). Gao ZS, Liu Y and Feng Y received funds from The Ministry of Science and Technology China (2019YFE0106600). Wang XY received a grant from Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201826). Rudolf Valenta has received research grants from Viravaxx, Vienna, Austria and HVD Life Sciences, Vienna, Austria and serves as a consultant for Viravaxx. Susanne Vrtala received funds from the Austrian government (CN 14/2020). A patent for Artemisia pollen allergen nsLTP quantification by ELISA has been applied in China (202011210352.1, pending) by ZS Gao, L Zhao, BY Gao and WY Fu. All other authors declare no conflict of interest. Funding Information: We thank professor Richard E. Goodman, Chairman of the Executive Committee of WHO/IUIS Allergen Nomenclature Sub-committee for evaluating and including new allergens reported in this paper. Dr. Ma Yintao participated in the sequencing of putative allergen genes with genomic DNAs. The authors thank Lingying Wu, Yifei Wang and Xiaojing Du for their assistance in sample collection and testing. Publisher Copyright: © 2020, The Author(s).

PY - 2020/12

Y1 - 2020/12

N2 - BACKGROUND: Artemisia weed pollen allergy is important in the northern hemisphere. While over 350 species of this genus have been recorded, there has been no full investigation into whether different species may affect the allergen diagnosis and treatment. This study aimed to evaluate the variations in amino acid sequences and the content of major allergens, and how these affect specific IgE binding capacity in representative Artemisia species.METHODS: Six representative Artemisia species from China and Artemisia vulgaris from Europe were used to determine allergen amino acid sequences by transcriptome, gene sequencing and mass spectrometry of the purified allergen component proteins. Sandwich ELISAs were developed and applied for Art v 1, Art v 2 and Art v 3 allergen quantification in different species. Aqueous pollen extracts and purified allergen components were used to assess IgE binding by ELISA and ImmunoCAP with mugwort allergic patient serum pools and individual sera from five areas in China.RESULTS: The Art v 1 and Art v 2 homologous allergen sequences in the seven Artemisia species were highly conserved. Art v 3 type allergens in A. annua and A. sieversiana were more divergent compared to A. argyi and A. vulgaris. The allergen content of Art v 1 group in the seven extracts ranged from 3.4% to 7.1%, that of Art v 2 from 1.0% to 3.6%, and Art v 3 from 0.3% to 10.5%. The highest IgE binding potency for most Chinese Artemisia allergy patients was with A. annua pollen extract, followed by A. vulgaris and A. argyi, with A. sieversiana significantly lower. Natural Art v 1-3 isoallergens from different species have almost equivalent IgE binding capacity in Artemisia allergic patients from China.CONCLUSION AND CLINICAL RELEVANCE: There was high sequence similarity but different content of the three group allergens from different Artemisia species. Choice of Artemisia annua and A. argyi pollen source for diagnosis and immunotherapy is recommended in China.

AB - BACKGROUND: Artemisia weed pollen allergy is important in the northern hemisphere. While over 350 species of this genus have been recorded, there has been no full investigation into whether different species may affect the allergen diagnosis and treatment. This study aimed to evaluate the variations in amino acid sequences and the content of major allergens, and how these affect specific IgE binding capacity in representative Artemisia species.METHODS: Six representative Artemisia species from China and Artemisia vulgaris from Europe were used to determine allergen amino acid sequences by transcriptome, gene sequencing and mass spectrometry of the purified allergen component proteins. Sandwich ELISAs were developed and applied for Art v 1, Art v 2 and Art v 3 allergen quantification in different species. Aqueous pollen extracts and purified allergen components were used to assess IgE binding by ELISA and ImmunoCAP with mugwort allergic patient serum pools and individual sera from five areas in China.RESULTS: The Art v 1 and Art v 2 homologous allergen sequences in the seven Artemisia species were highly conserved. Art v 3 type allergens in A. annua and A. sieversiana were more divergent compared to A. argyi and A. vulgaris. The allergen content of Art v 1 group in the seven extracts ranged from 3.4% to 7.1%, that of Art v 2 from 1.0% to 3.6%, and Art v 3 from 0.3% to 10.5%. The highest IgE binding potency for most Chinese Artemisia allergy patients was with A. annua pollen extract, followed by A. vulgaris and A. argyi, with A. sieversiana significantly lower. Natural Art v 1-3 isoallergens from different species have almost equivalent IgE binding capacity in Artemisia allergic patients from China.CONCLUSION AND CLINICAL RELEVANCE: There was high sequence similarity but different content of the three group allergens from different Artemisia species. Choice of Artemisia annua and A. argyi pollen source for diagnosis and immunotherapy is recommended in China.

UR - http://www.scopus.com/inward/record.url?scp=85096195535&partnerID=8YFLogxK

U2 - 10.1186/s13601-020-00354-7

DO - 10.1186/s13601-020-00354-7

M3 - Journal article

C2 - 33292509

SN - 2045-7022

VL - 10

SP - 50

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

IS - 1

M1 - 50

ER -

Variation in IgE binding potencies of seven Artemisia species depending on content of major allergens

Abstract

Access to Document

Other files and links

Fingerprint

Cite this